Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boots Centre for Innovation appoints scientific advisor, link to industry

This article was originally published in Clinica

Executive Summary

The UK's Boots Centre for Innovation has appointed James Ellis as a second, concurrent scientific advisor, in a move that is said to respond to a "huge response from innovators". His remit will be to work, alongside existing scientific advisor Ryan Bamsey, with business development managers, academics and industry to identify new product opportunities and encourage entrepreneurs to bring their pioneering ideas forward. Having worked for a number of university spin-out companies, Dr Ellis is said to have a "thorough knowledge of the difficulties entrepreneurs often face in finding a route to market". The Swansea, Wales-based Boots Centre for Innovation was set up in 2007 to identify and facilitate the development of pioneering healthcare products, and claims to have received more than 400 proposals.

You may also be interested in...

Milan Will Host The Global Generics & Biosimilars Awards 2020

Informa Pharma Intelligence has officially launched the seventh Global Generics & Biosimilars Awards, which will take place in October 2020 in Milan, Italy.

Mylan Weighs In On Coronavirus Drug Shortage Concerns

Hours before the US FDA confirmed the first drug shortage due to active pharmaceutical ingredient constraints because of the coronavirus situation in China, generics industry leader Mylan came under pressure about the potential impact on its business. 

Eyes On Pricing As Zolgensma Moves Closer To Japan Market

Government advisory committee gives initial nod to what will become Japan’s most expensive single drug, but reimbursement pricing could come in for close scrutiny.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts